WHY IT MATTERS: Women with endometriosis who are considering CBD as part of their pain management may soon have access to NHS-level clinical trial data to inform conversations with their physicians about safety and dosing. CLINICAL OVERVIEW: Endometriosis affects roughly one in ten women of reproductive age and remains chronically undertreated, with many patients cycling through years of hormonal therapies and surgical interventions before achieving meaningful relief. CBD has emerged as a candidate for managing the chronic pelvic pain and inflammatory burden associated with endometriosis, partly through its interactions with the endocannabinoid system, which is increasingly understood to play a role in uterine function and pain signaling.